Drugs / OPB-201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07664735 | Jun 2026 → Jun 2030 expected | endometrial cancer, ovarian cancer | Outpace Bio, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OPB-201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07664735 ↗ |
| Modality | Cell therapy | “an autologous PReferentially expressed Antigen of MElanoma (PRAME) T cell receptor (TCR) T cell therapy” NCT07664735 ↗ |
| Target | PRAME | “a TCR specific for a peptide derived from PRAME” NCT07664735 ↗ |